The tumor ECM structures, namely, the ECM-rich regions, are not typically targeted in cancer therapeutics; thus, even if cancer cells are removed, patients are left with extremely stiff and large fibronectin-rich structures in their lungs. The gene discussed is FN1; the disease is neoplasm.